Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 66 clinical trials
None
CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Hematological Malignancies

A Study of CD19/BCMA-targeted CAR-T Cells Combined With Dasatinib for Patients With Relapsed and/or Refractory B-cell Acute Lymphoblastic Leukemia, B-cell Non-Hodgkin's Lymphoma and Multiple

  • 0 views
  • 26 Jan, 2021
  • 1 location
None
A Study of CC-98633 BCMA-targeted Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed and/or Refractory Multiple Myeloma

This is a Phase 1, multicenter, open-label study of CC-98633, BCMA-Targeted NEX-T Chimeric Antigen Receptor (CAR) T Cells, in subjects with relapsed and/or refractory multiple myeloma.

proteasome inhibitor
lenalidomide
bcma
refractory multiple myeloma
chemotherapy regimen
  • 0 views
  • 18 Sep, 2021
  • 11 locations
None
A Phase 1/2 Study of a Fully Human BCMA-targeting CAR (CT103A) in Patients With Relapsed/Refractory Multiple Myeloma (FUMANBA-1)

This study is a single-armed, open-label, multicenter Phase 1/2 study to evaluate the efficacy and safety of CT103A in subjects with relapsed and refractory MM.

refractory multiple myeloma
chemotherapy regimen
immunohistochemistry
erythropoietin
neutrophil count
  • 0 views
  • 29 Nov, 2021
  • 14 locations
None
Safety and Efficacy of CT103A Cells for Relapsed/Refractory Antibody-associated Idiopathic Inflammatory Diseases of the Nervous System

produced by plasma cells (effector B cells) against aquaporin-4 (AQP4) water channels on astrocytes has been identified as the main characteristic of NMOSD physiology. B-cell maturation antigen (BCMA) is

neurological disorders
nervous
cyclophosphamide
electrolytes
neuritis
  • 0 views
  • 01 Dec, 2021
  • 1 location
None
Study of Belantamab Mafodotin as Pre- and Post-autologous Stem Cell Transplant and Maintenance for Multiple Myeloma

This is a single-institution, single-arm, phase 2 study in which belantamab mafodotin (GSK2857916), an antibody-drug conjugate targeting B-cell maturation antigen (BCMA), will be administered to

cell transplantation
progressive disease
lenalidomide
bone marrow procedure
melphalan
  • 0 views
  • 02 Jun, 2021
  • 1 location
None
A Study of LCAR-B38M CAR-T Cells a Chimeric Antigen Receptor T-cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Chinese Participants With Relapsed or Refractory Multiple Myeloma

The purpose of this study is to evaluate the efficacy and safety of LCAR-B38M chimeric antigen receptor T (CAR-T) cells.

bcma
refractory multiple myeloma
proteasome inhibitor
progressive disease
immunomodulatory imide drug
  • 7 views
  • 19 Nov, 2021
  • 8 locations
None
An Open-label Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments

specifically to B cell maturation antigen (BCMA) expressed on tumor cells of all participants with multiple myeloma. This is a Phase 1, open label, dose escalation study to investigate safety, tolerability

proteasome inhibitor
tumor cells
immunoglobulins
alkylating agents
cancer
  • 10 views
  • 30 Jul, 2021
  • 3 locations
None
A Study of TNB-383B in Subjects With Relapsed or Refractory Multiple Myeloma

This is a phase 1, open-label study evaluating the safety, clinical pharmacology and clinical activity of TNB-383B, a BCMA x CD3 T-cell engaging bispecific antibody, in subjects with relapsed or

bone marrow transplant
calcium
tumor cells
serum calcium
refractory multiple myeloma
  • 10 views
  • 12 Nov, 2021
  • 6 locations
None
Belantamab Mafodotin Lenalidomide and Daratumumab for the Treatment of Relapsed Refractory or Previously Untreated Multiple Myeloma

belantamab, linked to a chemotherapy drug, called mafodotin. Belantamab is a form of targeted therapy because it attaches to specific molecules (receptors) on the surface of cancer cells, known as BCMA

hypertension
chemotherapy regimen
lenalidomide
corticosteroids
dexamethasone
  • 0 views
  • 18 Oct, 2021
  • 1 location
None
A Study of Belantamab Mafodotin (GSK2857916) in Multiple Myeloma Participants With Normal and Varying Degree of Impaired Renal Function

Belantamab mafodotin (GSK2857916) is an antibody-drug conjugate (ADC) containing humanized anti- B-cell maturation antigen (BCMA) monoclonal antibody (mAb). Renal impairment is a major

monoclonal antibodies
lenalidomide
ixazomib
refractory multiple myeloma
bcma
  • 0 views
  • 18 Nov, 2021
  • 19 locations